Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate

Palada Pitakkitnukun,Thanakit Pongpitakmetha,Thitima Benjachat Suttichet,Warumphon Sukkummee,Pajaree Chariyavilaskul,Chantana Polprasert

DOI: https://doi.org/10.1038/s41598-024-60334-w

IF: 4.6

2024-04-28

Scientific Reports

Abstract:High-dose methotrexate (HD-MTX) is a widely used chemotherapy regimen for hematologic malignancies such as lymphomas and acute lymphoblastic leukemia, but its use can lead to adverse effects, including acute kidney injury (AKI), impaired liver function, and mucositis, causing extended hospital stays and delayed subsequent chemotherapy. Our study aimed to investigate the predictive factors for renal toxicities associated with HD-MTX in Thai patients undergoing treatment for hematologic malignancies. We enrolled 80 patients who underwent MTX-containing regimens, analyzing 132 chemotherapy cycles. The most common disease was primary central nervous system lymphoma (33%). Genetic polymorphisms were examined using the MassARRAY ® system, identifying 42 polymorphisms in 25 genes. Serum creatinine and MTX levels were measured 24 and 48 h after MTX administration. For the primary outcome, we found that the allele A of MTRR rs1801394 was significantly related to renal toxicity (odds ratio 2.084 (1.001–4.301), p -value 0.047). Patients who exceeded the MTX threshold levels at 24 h after the dose had a significantly higher risk of renal toxicity (OR (95%CI) = 6.818 (2.350–19.782), p < 0.001). Multivariate logistic regression analysis with a generalized estimated equation revealed hypertension and age as independent predictors of increased MTX levels at 24 h after the given dose.

multidisciplinary sciences

What problem does this paper attempt to address?

This paper aims to explore the predictive factors of nephrotoxicity associated with high - dose methotrexate (HD - MTX) treatment, especially in Thai patients receiving treatment for hematological malignancies. Specifically, the main objective of the study was to investigate the association between genetic variations related to the methotrexate metabolic pathway and nephrotoxicity. Secondary objectives included evaluating the relationship between methotrexate levels 24 hours after administration and serum creatinine levels, as well as the relationship between methotrexate levels and other clinical data (such as demographic data, disease type, chemotherapy regimen, methotrexate dose, laboratory indicators, baseline creatinine level, and creatinine level after methotrexate administration).

### Main research questions
1. **Relationship between genetic variation and nephrotoxicity**:
- The study analyzed 42 gene polymorphisms, involving 25 genes, to determine which genetic variations were associated with nephrotoxicity.
- Particular attention was paid to the significant relationship between the MTRR rs1801394 allele A and nephrotoxicity (odds ratio 2.084 (1.001 - 4.301), p - value 0.047).

2. **Relationship between methotrexate level and nephrotoxicity**:
- Patients with methotrexate levels exceeding the threshold 24 hours after administration had a significantly increased risk of nephrotoxicity (odds ratio 6.818 (2.350 - 19.782), p - value < 0.001).

3. **Relationship between other clinical factors and methotrexate level**:
- Multivariate logistic regression analysis showed that hypertension and age were independent predictors of elevated methotrexate levels 24 hours after administration.

### Secondary research questions
- **Relationship between methotrexate level and serum creatinine level**:
- Evaluate the relationship between methotrexate levels 24 hours and 48 hours after administration and serum creatinine levels.
- **Relationship between methotrexate level and other clinical data**:
- Evaluate the relationship between methotrexate levels and demographic data, disease type, chemotherapy regimen, methotrexate dose, laboratory indicators, baseline creatinine level, and creatinine level after methotrexate administration.

Through these studies, the authors hope to provide more accurate guidance for clinicians so that they can better predict and manage the risk of nephrotoxicity when using high - dose methotrexate to treat hematological malignancies.